Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13
Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13
复制标题
DOI：
10.1182/blood-2008-04-152678
复制
发表时间：
2009-01-29
期刊：
影响因子：
20.3
通讯作者：
Blum, William
中科院分区：
文献类型：
--
作者：
Fehniger, Todd A.;Byrd, John C.;Blum, William
急性髓系白血病 (AML) 患者经常因难治性疾病、复发或毒性而导致化疗失败。在老年 AML 患者（年龄 > 60 岁）中，长期幸存者很少。来那度胺是 AML 研究的候选药物，因为它在 5q 染色体异常的相关疾病、骨髓增生异常综合征 (MDS) 中的临床活性。我们报告了 2 名老年 AML 患者接受高剂量、单药来那度胺治疗后诱导了持续的形态学和细胞遗传学完全缓解；每个患者都有 13 三体性作为唯一的细胞遗传学异常。我们首次证明来那度胺在这种低风险细胞遗传学 AML 亚型中具有临床活性。本文描述的临床试验已在 www.clinicaltrials.gov 注册，标识符为 NCT00466895 和 NCT00546897。 （血。2009；113：1002-1005）
Patients with acute myeloid leukemia (AML) frequently fail chemotherapy due to refractory disease, relapse, or toxicity. Among older AML patients (age > 60 years), there are few long-term survivors. Lenalidomide is a candidate for study in AML based on its clinical activity in a related disorder, myelodysplastic syndrome (MDS), with the 5q- chromosomal abnormality. We report induction of sustained morphologic and cytogenetic complete remission in 2 older AML patients treated with high-dose, single-agent lenalidomide; each patient had trisomy 13 as the sole cytogenetic abnormality. We show for the first time that lenalidomide has clinical activity in this poor-risk cytogenetic subset of AML. The clinical trials described in this paper have been registered with www.clinicaltrials.gov under identifiers NCT00466895 and NCT00546897. (Blood. 2009;113:1002-1005)